Detailed Mechanism Funding and Narrative

Years of mechanism: 2011 2012 2013 2014 2015 2016 2017

Details for Mechanism ID: 13546
Country/Region: Kenya
Year: 2016
Main Partner: Henry M. Jackson Foundation for the Advancement of Military Medicine
Main Partner Program: NA
Organizational Type: Private Contractor
Funding Agency: USDOD
Total Funding: $3,853,364 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $462,280
Care: Orphans and Vulnerable Children (HKID) $342,714
Care: TB/HIV (HVTB) $100,356
Care: Pediatric Care and Support (PDCS) $90,583
Strategic Information (HVSI) $464,610
Sexual Prevention: Abstinence/Be Faithful (HVAB) $45,000
Testing: HIV Testing and Counseling (HVCT) $116,613
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $361,113
Treatment: Adult Treatment (HTXS) $1,779,097
Treatment: Pediatric Treatment (PDTX) $90,998
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST Age/sex: <1 2017 934
HTS_TST Age/sex: 1-9 2017 3,397
HTS_TST Age/sex: 10-14 Female 2017 1,501
HTS_TST Age/sex: 10-14 Male 2017 1,128
HTS_TST Age/sex: 15-19 Female 2017 3,000
HTS_TST Age/sex: 15-19 Male 2017 2,252
HTS_TST Age/sex: 20-24 Female 2017 6,342
HTS_TST Age/sex: 20-24 Male 2017 5,593
HTS_TST Age/sex: 25-49 Female 2017 8,969
HTS_TST Age/sex: 25-49 Male 2017 8,965
HTS_TST Age/sex: 50+ Female 2017 2,292
HTS_TST Age/sex: 50+ Male 2017 2,285
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 3,667
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 3,299
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 20,640
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 19,052
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 46,658
HTS_TST Service Delivery Point (Community): Other 2017 1,860
HTS_TST Service Delivery Point (Facility): Index testing 2017 5,563
HTS_TST Service Delivery Point (Facility): Inpatient 2017 1,993
HTS_TST Service Delivery Point (Facility): Other PITC 2017 17,677
HTS_TST Service Delivery Point (Facility): Outpatient 2017 10,912
HTS_TST Service Delivery Point (Facility): Pediatric 2017 1,566
HTS_TST Service Delivery Point (Facility): PMTCT 2017 3,483
HTS_TST Service Delivery Point (Facility): VCT 2017 3,604
HTS_TST Sum of Age/Sex disaggregates 2017 42,327
HTS_TST Sum of Aggregated Age/Sex <15 2017 6,966
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 39,692
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 46,658
HTS_TST Test Result by Aggregated Age and Sex: Negative <15 Female 2017 1,408
HTS_TST Test Result by Aggregated Age and Sex: Negative <15 Male 2017 2,111
HTS_TST Test Result by Aggregated Age and Sex: Negative 15+ Female 2017 9,579
HTS_TST Test Result by Aggregated Age and Sex: Negative 15+ Male 2017 14,369
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Female 2017 68
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Male 2017 69
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Female 2017 141
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Male 2017 141
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Female 2017 353
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Male 2017 352
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Female 2017 553
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Male 2017 548
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Female 2017 138
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Male 2017 135
HTS_TST_POS Test Result by Age: Positive: <1 2017 69
HTS_TST_POS Test Result by Age: Positive: 1-9 2017 211
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 211
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 205
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 1,184
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 1,178
OVC_SERV Age/Sex: 18+ Female 2017 1,507
OVC_SERV Age/Sex: 18+ Male 2017 1,632
OVC_SERV By Aggregated Age/Sex: <18 Female 2017 1,999
OVC_SERV By Aggregated Age/Sex: <18 Male 2017 2,165
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2017 7,303
OVC_SERV Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17 2017 93
OVC_SERV Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24 2017 319
OVC_SERV Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14 2017 94
OVC_SERV Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17 2017 604
OVC_SERV Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24 2017 94
OVC_SERV Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14 2017 2,726
OVC_SERV Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17 2017 8,272
OVC_SERV Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24 2017 10,462
OVC_SERV Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14 2017 280
OVC_SERV Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17 2017 558
OVC_SERV Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14 2017 280
OVC_SERV Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17 2017 464
OVC_SERV Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24 2017 280
OVC_SERV Sum of Age/Sex disaggregates 2017 3,139
PMTCT_ART Already on ART at beginning of current pregnancy 2017 437
PMTCT_ART New on ART 2017 476
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 3,505
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 215
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 516
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 149
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 56
PMTCT_EID Sum of Infant Age disaggregates 2017 731
PMTCT_STAT By Age (DREAMS SNUs ONLY): <15 2017 36
PMTCT_STAT By Age (DREAMS SNUs ONLY): 15-19 2017 155
PMTCT_STAT By Age (DREAMS SNUs ONLY): 20-24 2017 1,035
PMTCT_STAT By Age (DREAMS SNUs ONLY): 25-49 2017 1,812
PMTCT_STAT By Age (DREAMS SNUs ONLY): 50+ 2017 467
PMTCT_STAT By: Known positives at entry 2017 233
PMTCT_STAT By: Number of new positives identified 2017 152
PMTCT_STAT Number of new ANC and L&D clients 2017 3,505
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 3,505
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: <15 2017 4
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 15-19 2017 24
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 20-24 2017 55
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 25-49 2017 74
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 50+ 2017 30
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: <15 2017 3
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 15-19 2017 14
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 20-24 2017 47
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 25-49 2017 56
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 50+ 2017 15
PMTCT_STAT Sum of Positives Status disaggregates 2017 385
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: <15 2017 36
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: <15-19 2017 155
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: 20-24 2017 1,035
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: 25-49 2017 1,812
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: 50+ 2017 467
PP_PREV Aggregated Age/sex: <15 Female 2017 1,060
PP_PREV Aggregated Age/sex: 15+ Female 2017 2,114
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2017 3,174
PP_PREV Total number of people in the target population 2017 3,174
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 23
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 45
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 21
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 41
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 130
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 130
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 9,441
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 280
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 941
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 8,220
TB_SCREENDX Screen Result: Screened Positive for TB 2017 9,441
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 7,276
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 3,416
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 550
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 526
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 11,768
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 73
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 185
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 75
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 181
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 514
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 514
TX_CURR Age/Sex: <1 2017 42
TX_CURR Age/Sex: <1-9 2017 698
TX_CURR Age/Sex: 10-14 Female 2017 174
TX_CURR Age/Sex: 10-14 Male 2017 168
TX_CURR Age/Sex: 15-19 Female 2017 155
TX_CURR Age/Sex: 15-19 Male 2017 86
TX_CURR Age/Sex: 20-24 Female 2017 640
TX_CURR Age/Sex: 20-24 Male 2017 217
TX_CURR Age/Sex: 25-49 Female 2017 5,428
TX_CURR Age/Sex: 25-49 Male 2017 2,299
TX_CURR Age/Sex: 50+ Female 2017 1,047
TX_CURR Age/Sex: 50+ Male 2017 814
TX_CURR Aggregated Age/Sex: <15 Female 2017 550
TX_CURR Aggregated Age/Sex: <15 Male 2017 526
TX_CURR Aggregated Age/Sex: 15+ Female 2017 7,257
TX_CURR Aggregated Age/Sex: 15+ Male 2017 3,416
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 11,768
TX_CURR Sum of age/sex disaggregates 2017 241
TX_CURR Sum of Aggregated Age/Sex <15 2017 1,076
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 10,673
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 11,749
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 120
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 112
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 1,516
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 714
TX_NEW By Age/Sex: <1 2017 7
TX_NEW By Age/Sex: 1-9 2017 144
TX_NEW By Age/Sex: 10-14 Female 2017 37
TX_NEW By Age/Sex: 10-14 Male 2017 36
TX_NEW By Age/Sex: 15-19 Female 2017 32
TX_NEW By Age/Sex: 15-19 Male 2017 20
TX_NEW By Age/Sex: 20-24 Female 2017 135
TX_NEW By Age/Sex: 20-24 Male 2017 50
TX_NEW By Age/Sex: 25-49 Female 2017 1,131
TX_NEW By Age/Sex: 25-49 Male 2017 491
TX_NEW By Age/Sex: 50+ Female 2017 203
TX_NEW By Age/Sex: 50+ Male 2017 176
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 2,462
TX_NEW Sum of Age/Sex disaggregates 2017 2,311
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 2,462
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 10,591
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 10,591
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 594
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 574
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 6,211
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 3,212
TX_PVLS Numerator: Indication: Routine 2017 7,556
TX_PVLS Numerator: Indication: Targeted 2017 3,235
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 594
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 574
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 6,211
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 3,212
TX_PVLS_den Denominator: Indication: Routine 2017 7,556
TX_PVLS_den Denominator: Indication: Targeted 2017 3,035
TX_RET Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 6
TX_RET Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 133
TX_RET Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 33
TX_RET Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 32
TX_RET Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 29
TX_RET Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 15
TX_RET Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 121
TX_RET Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 34
TX_RET Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,021
TX_RET Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 447
TX_RET Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 198
TX_RET Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 154
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 107
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 99
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,368
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 648
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 2,222
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 2,222
TX_RET_den Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 6
TX_RET_den Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 133
TX_RET_den Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 33
TX_RET_den Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 32
TX_RET_den Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 29
TX_RET_den Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 18
TX_RET_den Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 121
TX_RET_den Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 31
TX_RET_den Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,021
TX_RET_den Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 447
TX_RET_den Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 198
TX_RET_den Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 153
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 107
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 99
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,368
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 648
Cross Cutting Budget Categories and Known Amounts Total: $120,000
Food and Nutrition: Policy, Tools, and Service Delivery $50,000
Food and Nutrition: Commodities $50,000
Key Populations: Sex Workers $15,000
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Monitoring and evaluation of SW programs
Gender: Gender Equality $5,000
Equity in HIV prevention, care, treatment and support